The role of Pet-Ct in neuroendocrine tumors without an identified primary focus: A case report and review
Paper Details
The role of Pet-Ct in neuroendocrine tumors without an identified primary focus: A case report and review
Abstract
Neuroendocrine tumors are a rare group of heterogeneous tumors, mostly developed in the gastrointestinal and respiratory tract. These tumors show overexpression of somatostatin receptors on the cell membrane, in which type 2 SSTRs are more common. Functional imaging techniques are using for the NETs diagnosis and treatment. In this case a patient with neuroendocrine tumor (NET) without primary focus was admitted to the hospital due to recurrent episodes of cholecystitis. During diagnostic investigation incidentally anechoic foci in the patient’s liver were detected and pathological examination of this foci showed that it’s a metastasis of neuroendocrine tumor. The patient was previously investigated for the primary focus identification of NET, but no significant outcome was found. Hence, we used SSTR-based PET/CT scan 68Ga-DOTA-peptides, which showed the primary focus of NET in the tail of pancreas. Therefore, we concluded that the PET/CT scan 68Ga-DOTA-TATE showed significant outcome with identification of tumor localization.
Ambrosini V, Caplin M, Castaño JP, Christ E, Denecke T, Deroose CM, Dromain C, Falconi M, Grozinsky‐Glasberg S, Hicks RJ, Hofland J. 2024. Use and perceived utility of [18F] FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022. Journal of Neuroendocrinology 36(1), e13359.
Arrivi G, Specchia M, Pilozzi E, Rinzivillo M, Caruso D, Santangeli C, Prosperi D, Ascolese AM, Panzuto F, Mazzuca F. 2024. Diagnostic and Therapeutic Management of Primary Orbital Neuroendocrine Tumors (NETs): Systematic Literature Review and Clinical Case Presentation. Biomedicines 12(2), 379.
Di Franco M, Zanoni L, Fortunati E, Fanti S, Ambrosini V. 2024. Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update. Current Oncology Reports 2024, 1-13.
Ditonno F, Franco A, Manfredi C, Veccia A, Valerio M, Bukavina L, Zukowski LB, Vourganti S, Stenzl A, Andriole GL, Antonelli A. 2024. Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT. Prostate Cancer Prostatic Disease 27(1), 29-36.
Ghabra S, Ramamoorthy B, Andrews SG, Sadowski SM. 2024. Surgical Management and Long-Term Evaluation of Pancreatic Neuroendocrine Tumors. Surgical Clinics 104(4), 891-908.
Han S, Ryu J, Song SW, Kim JS, Ryu JS, Oh M. 2024. 68Ga-DOATATOC Brain PET/CT Imaging in a case of Dural Metastasis from Synovial Sarcoma. Nuclear Medicine and Molecular Imaging 2024, 1-7.
Has Simsek D, Guzel Y, Denizmen D, Sanli Y, Buyukkaya F, Kovan B, Komek H, Isik EG, Ozkan ZG, Kuyumcu S. 2024. The inferior performance of [68Ga] Ga-FAPI-04 PET/CT as a diagnostic and theranostic biomarker in [177Lu] Lu-DOTATATE refractory well-differentiated neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging 51(3), 828-40.
Huang J, Liu H, Yang D, Xu T, Wang J, Li J. 2024. Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study. Chinese Medical Journal 2024, 10-1097.
Marcus C, Muzahir S, Subramaniam RM. 2024. Quarter Century PET/Computed Tomography Transformation of Oncology: Neuroendocrine Tumors. PET Clinics 19(2), 187-196.
Pishdad R, Treglia G, Mehta A, Santhanam P. 2024. Somatostatin receptor imaging of thyroid tissue and differentiated thyroid cancer using gallium-68-labeled radiotracers—a review of clinical studies. Endocrine 18, 1-10.
Raynor WY, Kempf JS. 2024. Somatostatin Receptor PET Imaging of Physiologic and Benign Processes: Implications for Image Interpretation, Avoiding Pitfalls, and Clinical Applications. Applied Radiology 2, 53.
Søreide K, Stättner S, Hallet J. 2024. Surgery as a Principle and Technical Consideration for Primary Tumor Resection of Small Bowel Neuroendocrine Tumors. Annals of Surgical Oncology 31(2), 1125-1137.
Sugawara H, Kikkawa N, Ito K, Watanabe H, Kaku S, Akai H, Abe O, Watanabe SI, Yatabe Y, Kusumoto M. 2024. Is 18F-fluorodeoxyglucose PET recommended for small lung nodules? CT findings of 18F-fluorodeoxyglucose non-avid lung cancer. British Journal of Radiology 97(1154), 462-468.
Wedin M, Janson ET, Wallin G, Sundin A, Daskalakis K. 2024. Prevalence of metastases outside the liver and abdominal lymph nodes on 68Ga‐DOTATOC‐PET/CT in patients with small intestinal and pancreatic neuroendocrine tumours. Journal of Neuroendocrinology 36(5), e13391.
Tinatin Rizaeva, Daniyar Shahanov, Shafee Ur Rehman, Kudaibergen Osmonaliev, Nurlan Mannapuulu, Meder Melisbekov, Damir Abibillaev, 2024. The role of Pet-Ct in neuroendocrine tumors without an identified primary focus: A case report and review. Int. J. Biosci., 25(2), 25-30.
Copyright © 2024 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.